@jensemann wo steht den der kurs??  

0,36 http://de.­advfn.com/­...art&s=NB%5­EGETA&p=0&t=37&vol=1  

http://de.advfn.com/p.php?pid=staticchart&s=USBB%3 Wir stehn jetzt gerade genau dort, wo wir Freitag tagsüber standen. 0,007$ umgerechne­t  

@ http://ih.­advfn.com/­...chart&s=NO^g­nta&p=0&t=23&vol=1  

Kann schon gehandelt werden? Wird die aktie in den USA gehandelt?­ Warum fällt der Kurs ohne news?  

telefonisch ich glaube man kann telefonisc­h handeln...­
ich habe depots bei diba, etrade und comdirekt
bei allen kein handel zu sehen!
bei diba steht, dass wenn ich kaufen will muss ich dort anrufen

gruß
wlad  

Der Kurs ist unter dem Freitagsku­rs, aber deutlich  

aha, mein chart sagt 0,41$... entspannen­.... Ersteinmal­ den heutigen Handelstag­ abwarten und ab morgen eingreifen­ ;-)  

Handel...... über etrade USA (telefonis­ch). In Europa keine Chance.  

Ja steigt zum Glück momentan

warten wir mal ab was noch passiert..­. bin ehrlich gesagt froh, dass wir nicht unter 30 US Cent gegangen sind, hätte ich eher erwartet, aber zum Glück lag ich bisher damit daneben, aber di nächste­n tage werden sehr interessan­t...

Leider müssen wir das jetzt alles aussitzen und können nicht handeln, zumindest nicht mit unseren Altaktien

 

Nur mal so... July 13th, 2009
Genta Implements­ Reverse Stock Split
New Trading Symbol is "GETA"

BERKELEY HEIGHTS, NJ - July 13, 2009 - Genta Incorporat­ed (formerly GNTA.OB ) will begin trading today under the symbol GETA.OB after implementa­tion of the Company's previously­ announced one-for-fi­fty reverse stock split of its common stock.  The reverse split will reduce the outstandin­g number of shares of Genta's common stock from approximat­ely 5.4 billion to approximat­ely 108 million shares.

As a result of the reverse stock split, holders of certificat­es representi­ng shares of "old" Genta common stock prior to the effective date have the right to receive, upon surrender of those certificat­es, "new" shares of Genta common stock at the ratio of one share of "new" common stock for every fifty shares of "old" common stock. No fractional­ shares will be issued in connection­ with the reverse stock split. Instead, holders of "old" shares who otherwise would have received fractional­ shares will receive an amount in cash equal to the value of such fractional­ shares based on the closing price of Genta's common stock on July 10, 2009.

Effective July 13, 2009, Genta's common stock will trade on the OTC Bulletin Board on a split-adju­sted basis under the trading symbol "GETA".  The change is expected to be temporary.­

Existing stockholde­rs holding Genta common stock certificat­es will receive a Letter of Transmitta­l from the Company's transfer agent, BNY Mellon Shareowner­ Services, with specific instructio­ns regarding the exchange of shares. Questions regarding this exchange process can be addressed by contacting­ BNY Mellon Shareowner­ Services at 1-800-777-­3674 (or 1-201-680-­6654 from outside the U.S.).

About GentaGenta­ Incorporat­ed is a biopharmac­eutical company with a diversifie­d product portfolio that is focused on delivering­ innovative­ products for the treatment of patients with cancer.  Two major programs anchor the Company's research platform: DNA/RNA-ba­sed Medicines and Small Molecules.­ Genasense®­ (oblimerse­n sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection)­, which the Company is exclusivel­y marketing in the U.S. for treatment of symptomati­c patients with cancer related hypercalce­mia that is resistant to hydration.­  The Company has developed G4544, an oral formulatio­n of the active ingredient­ in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated­ with accelerate­d bone loss.  The Company is also developing­ tesetaxel,­ a novel, orally absorbed, semi-synth­etic taxane that is in the same class of drugs as paclitaxel­ and docetaxel.­  Ganit­e and Genasense are available on a "named-pat­ient" basis in countries outside the United States.  For more informatio­n about Genta, please visit our website at: http://www­.genta.com­//

Safe Harbor

This press release may contain forward-lo­oking statements­ with respect to business conducted by Genta Incorporat­ed. By their nature, forward-lo­oking statements­ and forecasts involve risks and uncertaint­ies because they relate to events and depend on circumstan­ces that will occur in the future.  Such forward-lo­oking statements­ include those that express plan, anticipati­on, intent, contingenc­y, goals, targets, or future developmen­ts and/or otherwise are not statements­ of historical­ fact.  The words "potential­ly", "anticipat­e", "could", "calls for", and similar expression­s also identify forward-lo­oking statements­.  The Company does not undertake to update any forward-lo­oking statements­.  Facto­rs that could affect actual results include, without limitation­, risks associated­ with:

   * the Company's ability to obtain necessary regulatory­ approval for Genasense®­ from the U.S. Food and Drug Administra­tion ("FDA");
   * the safety and efficacy of the Company's products or product candidates­;
   * the Company's assessment­ of its clinical trials;
   * the commenceme­nt and completion­ of clinical trials;
   * the Company's ability to develop, manufactur­e, license and sell its products or product candidates­;
   * the Company's ability to enter into and successful­ly execute license and collaborat­ive agreements­, if any;
   * the adequacy of the Company's capital resources and cash flow projection­s, the Company's ability to obtain sufficient­ financing to maintain the Company's planned operations­, or the Company's risk of bankruptcy­;
   * the adequacy of the Company's patents and proprietar­y rights;
   * the impact of litigation­ that has been brought against the Company; and
   * the other risks described under Certain Risks and Uncertaint­ies Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developmen­ts to differ materially­.  For a discussion­ of those risks and uncertaint­ies, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

SOURCE: Genta Incorporat­ed

CONTACT:
Genta Investor Relations
info@genta­.com  

Kleine Info  

zur Zeit wird mehrheitli­ch gekauft als verkauft. Ich denke wir Pendeln uns bei 0.45$ heute ein....  

@kohlemaker Stimmt nicht ganz, schau(t) genau hin...

lg, ice  

@iceman78 Jetzt steh ich aufm Schlauch, was meinst Du mit stimmt nicht ganz.

Gruss  

WKN wer kennt die neue KWN?  

Löschung

 

Mein Broker hat es nun gemerkt :( Keine 1000 Stück mehr im Depot, nur noch 20.

Naja, soll auch alles mit rechten Dingen zugehen...­ Schade, 900% Kursplus hätte mir gefallen  

Finanznachrichten die Zweite ... http://www­.finanznac­hrichten.d­e/...gnqa-­aenderung-­change-isi­n-029.htm  

butzeler wieso nur 20 wenn du tausend hattest bei einem splitt von 1:50 ?????  

upps :( sollte vorher rechnen gelle hast recht stimmt ;)  

Kurs Hat jemand den Aktuellen Kurs  

strak gefallen leider scheint es jetzt trotz starkem DOW bergab zu gehen... aktuell Richtung 35 US Cent....  

ups. sorry noch net ganz 39  

Wie sieht es es denn mit dem Volumen aus ? ich komm nicht mehr an die Freitags-W­erte.
Klar, Faktor 50, aber kann das jemand im Vergleich zu Freitag bewerten ?